Gt Biopharma, INC. 10-Q Filing
Ticker: GTBP · Form: 10-Q · Filed: Aug 14, 2024 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 10-Q |
| Filed Date | Aug 14, 2024 |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 10-Q filing submitted by Gt Biopharma, INC. (ticker: GTBP) to the SEC on Aug 14, 2024.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value per share GTBP Nasdaq Ca).
How long is this filing?
Gt Biopharma, INC.'s 10-Q filing is 15 pages with approximately 4,479 words. Estimated reading time is 18 minutes.
Where can I view the full 10-Q filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 4,479 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2024-08-14 16:00:40
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GTBP Nasdaq Ca
Filing Documents
- form10-q.htm (10-Q) — 924KB
- ex10-2.htm (EX-10.2) — 27KB
- ex10-3.htm (EX-10.3) — 32KB
- ex31-1.htm (EX-31.1) — 21KB
- ex31-2.htm (EX-31.2) — 20KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 6KB
- form10-q_002.jpg (GRAPHIC) — 66KB
- form10-q_003.jpg (GRAPHIC) — 15KB
- form10-q_004.jpg (GRAPHIC) — 85KB
- form10-q_005.jpg (GRAPHIC) — 15KB
- form10-q_006.jpg (GRAPHIC) — 12KB
- form10-q_013.jpg (GRAPHIC) — 260KB
- ex10-2_001.jpg (GRAPHIC) — 380KB
- ex10-2_002.jpg (GRAPHIC) — 338KB
- ex10-2_003.jpg (GRAPHIC) — 364KB
- ex10-2_004.jpg (GRAPHIC) — 414KB
- ex10-2_005.jpg (GRAPHIC) — 504KB
- ex10-2_006.jpg (GRAPHIC) — 428KB
- ex10-2_007.jpg (GRAPHIC) — 262KB
- ex10-2_008.jpg (GRAPHIC) — 89KB
- ex10-2_009.jpg (GRAPHIC) — 86KB
- ex10-2_010.jpg (GRAPHIC) — 495KB
- ex10-2_011.jpg (GRAPHIC) — 513KB
- ex10-2_012.jpg (GRAPHIC) — 459KB
- ex10-2_013.jpg (GRAPHIC) — 391KB
- ex10-2_014.jpg (GRAPHIC) — 490KB
- ex10-2_015.jpg (GRAPHIC) — 539KB
- ex10-2_016.jpg (GRAPHIC) — 515KB
- ex10-2_017.jpg (GRAPHIC) — 589KB
- ex10-2_018.jpg (GRAPHIC) — 438KB
- ex10-2_019.jpg (GRAPHIC) — 447KB
- ex10-2_020.jpg (GRAPHIC) — 529KB
- ex10-2_021.jpg (GRAPHIC) — 480KB
- ex10-2_022.jpg (GRAPHIC) — 408KB
- ex10-2_023.jpg (GRAPHIC) — 62KB
- ex10-2_024.jpg (GRAPHIC) — 389KB
- ex10-2_025.jpg (GRAPHIC) — 342KB
- ex10-2_026.jpg (GRAPHIC) — 303KB
- ex10-3_001.jpg (GRAPHIC) — 140KB
- ex10-3_002.jpg (GRAPHIC) — 153KB
- ex10-3_003.jpg (GRAPHIC) — 150KB
- ex10-3_004.jpg (GRAPHIC) — 161KB
- ex10-3_005.jpg (GRAPHIC) — 185KB
- ex10-3_006.jpg (GRAPHIC) — 137KB
- ex10-3_007.jpg (GRAPHIC) — 176KB
- ex10-3_008.jpg (GRAPHIC) — 173KB
- ex10-3_009.jpg (GRAPHIC) — 161KB
- ex10-3_010.jpg (GRAPHIC) — 149KB
- ex10-3_011.jpg (GRAPHIC) — 190KB
- ex10-3_012.jpg (GRAPHIC) — 168KB
- ex10-3_013.jpg (GRAPHIC) — 196KB
- ex10-3_014.jpg (GRAPHIC) — 88KB
- ex10-3_015.jpg (GRAPHIC) — 34KB
- ex10-3_016.jpg (GRAPHIC) — 142KB
- ex10-3_017.jpg (GRAPHIC) — 47KB
- ex10-3_018.jpg (GRAPHIC) — 73KB
- ex10-3_019.jpg (GRAPHIC) — 163KB
- ex10-3_020.jpg (GRAPHIC) — 145KB
- ex10-3_022.jpg (GRAPHIC) — 230KB
- ex10-3_023.jpg (GRAPHIC) — 205KB
- ex10-3_024.jpg (GRAPHIC) — 28KB
- 0001493152-24-032143.txt ( ) — 24857KB
- gtbp-20240630.xsd (EX-101.SCH) — 41KB
- gtbp-20240630_cal.xml (EX-101.CAL) — 36KB
- gtbp-20240630_def.xml (EX-101.DEF) — 163KB
- gtbp-20240630_lab.xml (EX-101.LAB) — 321KB
- gtbp-20240630_pre.xml (EX-101.PRE) — 247KB
- form10-q_htm.xml (XML) — 780KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 28
OTHER INFORMATION
PART II OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 29 Item 6. Exhibits 30
SIGNATURES
SIGNATURES 31 2 GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets June 30, 2024 December 31, 2023 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 9,249,000 $ 1,079,000 Short-term investments — 12,893,000 Prepaid expenses and other current assets 18,000 84,000 Total Current Assets 9,267,000 14,056,000 Operating lease right-of-use asset - 53,000 TOTAL ASSETS $ 9,267,000 $ 14,109,000 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,717,000 $ 4,328,000 Accrued expenses 1,765,000 1,195,000 Current operating lease liability — 58,000 Warrant liability 277,000 1,052,000 Total Current Liabilities 3,759,000 6,633,000 Stockholders' Equity Convertible Preferred stock, par value $ 0.01 , 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1,000 1,000 Common stock, par value $ 0.001 , 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 2,000 1,000 Additional paid in capital 693,546,000 689,539,000 Accumulated deficit ( 688,041,000 ) ( 682,065,000 ) Total Stockholders' Equity 5,508,000 7,476,000 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 9,267,000 $ 14,109,000 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations 2024 2023 2024 2023 For The Three Months Ended For the Six Months Ended June 30, June 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Operating Expenses: Research and development $ 1,784,000 $ 2,095,000 $ 2,561,000 $ 3,745,000 Selling, general and administrative (including $ 120,000 and $ 398,000 from stock compensation granted to officers, directors, a